Related Experiment Video

Updated: Jul 17, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

A new EGFR inhibitor induces apoptosis in colon cancer cells

N Calonghi1, E Pagnotta, C Parolin

  • 1Department of Biochemistry G. Moruzzi, University of Bologna, Bologna, Italy.

Biochemical and Biophysical Research Communications
|January 18, 2007
PubMed

Insights

A novel agent, FR18, shows promise in colon cancer treatment by inhibiting epidermal growth factor receptor (EGFR) signaling and inducing apoptosis at low concentrations. This new EGFR inhibitor offers potential therapeutic applications for colon cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeting the epidermal growth factor receptor (EGFR) is a key strategy in colon cancer therapy.
  • Existing EGFR inhibitors, including monoclonal antibodies (mAbs) and tyrosine kinase inhibitors, have shown limited clinical utility in colon cancer due to toxicity or inefficiency.

Purpose of the Study:

  • To investigate the therapeutic potential of FR18, a novel EGFR inhibitor with a naphthoquinone core, in colon cancer.
  • To evaluate the efficacy and mechanism of action of FR18 in a human colon carcinoma cell line.

Main Methods:

  • Utilized HT29 human colon carcinoma cells for in vitro studies.
  • Employed flow cytometry, immunoprecipitation, Western blot analysis, and confocal spectral microscopy to assess FR18's effects.
  • Investigated FR18's impact on EGF binding to EGFR and its effect on receptor kinase activity.

Main Results:

  • FR18 demonstrated significant activity at nanomolar concentrations (as low as 10 nM).
  • FR18 effectively inhibited EGF binding to EGFR without affecting the receptor's kinase activity.
  • FR18 induced apoptosis in colon cancer cells at concentrations ranging from 30 nM to 5 µM.

Conclusions:

  • FR18 exhibits potent anti-tumor activity against colon cancer cells.
  • FR18's mechanism involves inhibiting EGF binding and inducing apoptosis, suggesting a promising therapeutic application in colon cancer.
  • FR18 represents a potential new therapeutic agent for colon cancer treatment.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...